




















































positions	 in	 the	 protein6	 up	 to	whole	 genes5	 or	 pathways7	 (Fig.	 1a).	Many	 of	 the	 recently	 developed	
methods	 aim	 to	 find	 driver	 events	 at	 the	 subgene	 level.	 One	 advantage	 of	 such	 higher	 resolution	




























can	 only	 find	 clusters	 of	mutations	 that	 are	 linear	 in	 the	 primary	 sequence.	 Other	methods	 leverage	
information	from	3D	protein	structures	and	can	identify	spatial	patterns	that	are	discontinuous	along	the	




















encoded	 by	 a	 given	 gene.	 Their	 scope	 is	 more	 limited	 than	 that	 Type	 I	 algorithms,	 because	 Type	 II	







on	 the	 distance	 between	 residues	 in	 3D29	 or	 use	 network	 algorithms	 on	 the	 graph	 derived	 from	 the	
structure30.	 However,	 most	 Type	 II	 algorithms	 are	 designed	 to	 identify	 3D	 clusters	 using	 the	 protein	
structure	 directly	 and	 to	 calculate	 empirical	 P	 values	 by	 reshuffling	 the	mutations	 in	 the	 structure31.	
Nevertheless,	 the	 specific	 details	 of	 Type	 II	 algorithms	 can	 be	 very	 different,	 as	 some	 use	 spheres	 of	









approximately	 65%	 of	 the	 human	 proteome	 (Supplementary	 Fig.	 1).	 These	 regions	 can	 be	 protein	
domains18	or	post-translational	modification	sites20.	Type	III	algorithms	compare	the	number	of	mutations	
in	the	selected	region	with	that	of	the	rest	of	the	protein	to	determine	whether	there	is	enrichment	in	
somatic	mutations	 in	 specific	domains	or	 regions.	We	also	 include	 in	 this	category	methods	 that	align	













of	 CLUMPS,	 the	 number	 of	 proteins	 and	 structures	 that	 can	 be	 analyzed	 is	 higher,	 as	 CLUMPS	 uses	






In	 order	 to	 explore	 the	 strengths	 and	 limitations	 of	 each	 of	 these	 four	 categories,	 we	 compared	 the	
predictions	of	methods	covering	all	four	categories,	as	well	as	predictions	of	two	methods	that	rely	on	
whole-gene	analysis	(OncodriveFM	and	MutSigCV)5,34,	on	four	different	cancer	genomics	data	sets	from	
The	Cancer	Genome	Atlas1.	We	aimed	 to	 assess	 how	 the	 specific	 assumptions	 behind	 each	 algorithm	
affect	the	number	and	type	of	drivers	it	identifies.	In	our	analysis,	we	include	five	methods	that	belong	to	
Type	 I	 (Hotspot35,	 NMC15,	 OncodriveCLUST14,	MutSig-CL26	 and	 iSIMPRe22),	 four	 from	 Type	 II	 (iPAC29,	
GraphPAC30,	SpacePAC32	and	CLUMPS16),	three	from	Type	III	(e-Driver18,	ActiveDriver20	and	LowMACA19)	
and	one	from	Type	IV	(e-Driver3D21).		






identify	different	genes	than	the	other	 two	Type	 III	algorithms	 in	all	data	sets.	The	reasons	why	these	
algorithms	behave	differently	 from	 the	 rest	 of	methods	 from	 the	 same	 category	 could	 be	 varied.	 For	



















the	 complementarity	 between	methods	 from	different	 categories.	 Again,	 in	 the	 case	 of	GBM,	 Type	 II	
algorithms	 do	 not	 detect	 PIK3R1,	 because	 the	 missense	 mutations	 are	 spread	 throughout	 a	 large	
interface.	However,	Type	I,	Type	III	or	Type	IV	algorithms	detect	the	mutation	cluster	PIK3R1,	even	if	the	

























As	 for	 the	 individual	methods,	we	 observe	 a	 clear	 split	 in	 recall	 values	 between	 the	 two	whole-gene	
methods	and	any	of	the	subgene	algorithms,	with	the	former	having	higher	recall	values	than	those	of	the	





and	take	 into	account	only	 the	mutations	within	a	specific	gene.	While	 this	gives	an	advantage	to	 the	








Intrigued	 by	 the	 relatively	 low	 precision	 values	 of	 most	 subgene	 algorithms,	 we	 classified	 the	 genes	
identified	 by	 each	method	 into	 different	 categories	 (Fig.	 3b)	 depending	 on	 whether	 they	 are	 known	
somatic	drivers	in	that	specific	tissue	and	whether	they	are	affected	by	missense	mutations	or	through	
other	genomic	alterations	 (such	as	copy-number	variations	or	genomic	 rearrangements).	As	expected,	
many	of	 the	 identified	genes	are	known	 to	be	missense	 somatic	drivers	 in	 their	 corresponding	 tissue.	
However,	there	are	also	231	genes	that	are	predicted	to	be	drivers	by	at	least	one	method	and	that,	while	
they	do	not	have	any	known	driver	 roles	 in	 the	tissue	where	they	are	detected,	 they	are	 identified	as	
drivers	 in	 other	 tissues.	 A	 total	 of	 123	of	 these	 genes	 (53%)	 are	missed	by	whole-gene	methods	 but,	
nonetheless,	are	detected	by	subgene	algorithms	(Supplementary	Table	6).		
	




has	 been	 linked	 to	 breast	 cancer	 when	 amplified	 and	 to	 myeloproliferative	 syndromes	 when	 trans-	
located.	Nevertheless,	both	ActiveDriver	and	LowMACA	identified	a	small	cluster	of	mutations	in	its	kinase	
domain.	Another	unexpected	finding	was	that	several	genes	known	to	cause	cancer	through	germline	(but	
not	somatic)	mutations	were	 identified	by	some	of	 the	methods.	The	most	significant	example	of	 this	
category	is	CDK4.	Germline	mutations	in	this	gene	are	associated	with	familial	melanoma,	but	six	subgene	
algorithms	 identified	 CDK4	 as	 a	 likely	 driver	 in	 lung	 adenocarcinoma.	 Notably,	 some	 of	 the	 somatic	
mutations	affect	 the	 same	amino	acids	as	 the	germline	variations	associated	with	melanoma,	 such	as	
R24L.	
	
Regarding	 the	mode	of	 action	of	 the	detected	 genes,	 it	 has	 previously	 been	 suggested	 that	mutation	














different	subgene	methods	but	not	by	 the	methods	 that	work	at	 the	gene	resolution	 (Supplementary	
Table	7).		
Though	they	are	not	yet	part	of	the	CGC,	some	of	these	genes	have	been	reported	to	have	roles	in	cancer	

















are	 unknown.	 Many	 of	 such	 VUS	 are	 part	 of	 mutation	 clusters	 recognized	 as	 drivers	 by	 subgene	
algorithms,	and	this	immediately	raises	the	question	whether	these	mutations	can	act	as	drivers	in	the	
patients	that	carry	them.	Even	though	it	is	now	possible	to	systematically	test	some	of	these	mutations	











have	 the	highest	EGFR	protein	and	phosphorylation	 levels,	 suggesting	a	higher	activation	of	 the	EGFR	
pathway,	while	those	with	mutations	in	other	EGFR	regions	have	an	intermediate	phenotype	between	the	
interface-mutated	and	the	EGFR	wild-type	samples,	a	result	that	has	recently	been	verified	using	cancer	












have	different	degrees	of	 contribution	 to	 cancer	 growth.	 The	 results	of	 subgene	algorithms	provide	a	
natural	way	to	classify	mutations	in	well-established	cancer-driver	genes	as	either	mutations	that	happen	
in	clusters	or	hotspots	(and	more	likely	to	be	major	drivers)	and	those	that	happen	in	other	regions	of	the	
same	protein	and	are	 less	frequently	mutated	(more	 likely	to	have	a	 lower	driver	effect	or	to	even	be	

















for	 cancer	 research,	 including,	 but	 not	 limited	 to,	 advancing	 the	 continuing	 efforts	 to	 define	 how	
mutations	contribute	to	cancer	onset	and	progression.		
	
Also,	 while	 we	 have	 not	 explicitly	 explored	 this	 issue,	 it	 would	 likely	 be	 possible	 to	 apply	 the	 same	







to	 incorporate	 the	 methods,	 input,	 output	 and	 gold-standard	 data	 sets	 into	 the	 pan-European	
bioinformatics	 infrastructure	 ELIXIR.	 ELIXIR	 is	 currently	 developing	 a	 data	 warehouse	 for	 hosting	
continuous	 automated	 benchmarking	 efforts	 in	 this	 and	 other	 areas	 of	 life	 sciences;	 for	 example,	
homology	building,	in	close	collaboration	with	different	research	communities.	The	current	ELIXIR	data	
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breast	 adenocarcinoma	 (BRCA,	 n	 =	 982)47,	 bladder	 adenocarcinoma	 (BLCA,	 n	 =	 137)48	 and	 lung	
adenocarcinomas	 (LUAD,	 n	 =	 546)49.	 We	 used	 Intogen50	 to	 predict	 the	 location	 and	 impact	 of	 each	
mutation	 in	 the	 different	 protein	 isoforms	 from	 their	 genomic	 coordinates	 (Supplementary	 Fig.	 6).	

























least	 three	 different	 algorithms.	 This	 threshold	 was	 defined	 to	 minimize	 the	 risk	 of	 overfitting.	 This	
approach	has	previously	proven	useful	in	detecting	cancer	driver	genes52.		
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